Table 3.
Comparison of tumour HPV DNA, p16 and cyclin D1 status between outcome groups 1 and 2
| Total (N=60) | Group 1 (N=39, 65%) | Group 2 (N=21, 35%) | P value | |
|---|---|---|---|---|
|
HPV-HR |
|
|
|
|
| Positive |
23 (56) |
14 (61) |
9 (50) |
0.54 |
| Negative |
18 (44) |
9 (39) |
9 (50) |
|
|
HPV-16/18 |
|
|
|
|
| Positive |
15 (37) |
8 (35) |
7 (39) |
1 |
| Negative |
26 (63) |
15 (65) |
11 (61) |
|
|
p16 |
|
|
|
|
| Positive |
27 (66) |
16 (70) |
11 (61) |
0.74 |
| Negative |
14 (34) |
7 (30) |
7 (39) |
|
|
Cyclin D1 |
|
|
|
|
| Positive |
12 (29) |
4 (17) |
8 (44) |
|
| Negative | 29 (71) | 19 (83) | 10 (56) | 0.09 |